1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration - Drugs In Development, 2022, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Age Related Macular Degeneration - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 8, 6, 95, 34 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 1 molecules, respectively.
Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Age Related Macular Degeneration - Overview
- Age Related Macular Degeneration - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Age Related Macular Degeneration - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Age Related Macular Degeneration - Companies Involved in Therapeutics Development
- Age Related Macular Degeneration - Drug Profiles
- Age Related Macular Degeneration - Dormant Projects
- Age Related Macular Degeneration - Discontinued Products
- Age Related Macular Degeneration - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Age Related Macular Degeneration, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..2)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Age Related Macular Degeneration - Dormant Projects, 2022
- Age Related Macular Degeneration - Discontinued Products, 2022
- Number of Products under Development for Age Related Macular Degeneration, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- Abfero Pharmaceuticals Inc
- Abzyme Therapeutics LLC
- Acahealth Pharma and Biotech Co Ltd
- Aerie Pharmaceuticals Inc
- Alexion Pharmaceuticals Inc
- Alkeus Pharmaceuticals Inc
- Amarna Therapeutics BV
- AMD Therapeutics LLC
- AmMax Bio Inc
- Amyndas Pharmaceuticals LLC
- Amytrx Therapeutics Inc
- AngioGenex Inc
- Anida Pharma Inc
- Applied Genetic Technologies Corp
- Aptamer Sciences Inc
- Ascentage Pharma Group International
- Autophagy Science Co Ltd
- Avirmax Inc
- Baltymas UAB
- Beijing StarMab BioMed Technology Ltd
- BellBrook Labs LLC
- BenoBio Co Ltd
- Biokine Therapeutics Ltd
- Biomics Biotechnologies Co Ltd
- BioXpress Therapeutics SA
- Bonac Corp
- BrainEver SAS
- Breye Therapeutics ApS
- Bridge Biotherapeutics Inc
- Broadwing Bio
- Carmine Therapeutics Inc
- CDR-Life Inc
- Celon Pharma SA
- Celros Biotech Co Ltd
- Character Biosciences Co
- Charlesson LLC
- Chong Kun Dang Pharmaceutical Corporation
- Clayton Biotechnologies Inc
- Complement Therapeutics Ltd
- ConeSight Therapeutics
- Curative Biotechnology Inc
- CureLab Oncology Inc
- Daiichi Sankyo Co Ltd
- EirGenix Inc
- Epygen Biotech Pvt Ltd
- Excitant Therapeutics LLC
- Exegenesis Bio Inc
- Eye Bio Korea Co Ltd
- F. Hoffmann-La Roche Ltd
- Feramda Ltd
- Galimedix Therapeutics Ltd
- Generoath Co Ltd
- Glaceum Inc
- Great Bay Bio Holdings Ltd
- Hanlim Pharm Co Ltd
- ICM Co Ltd
- Iconic Therapeutics Inc
- Immupharma Plc
- Inflammasome Therapeutics Inc
- Inflammx Therapeutics Inc
- Jecho Biopharmaceuticals Co Ltd
- Jenivision Inc
- JW Pharmaceutical Corp
- Kala Pharmaceuticals Inc
- Kiora Pharmaceuticals Inc
- Lead Discovery Center GmbH
- Lineage Cell Therapeutics Inc
- Lysoclear Inc
- Mabion SA
- maintect GmbH
- MD Healthcare Inc
- MDimune Inc
- Mediolanum farmaceutici SpA
- MetiMedi Pharmaceuticals Co Ltd
- MitoImmune Therapeutics Inc
- Mitsubishi Tanabe Pharma Corp
- Mor Research Applications Ltd
- Nextgen Bioscience
- NGM Biopharmaceuticals Inc
- Novartis AG
- Noveome Biotherapeutics Inc
- OliPass Corporation
- Omeros Corp
- Oncosimis Biotech Pvt Ltd
- Opsis Therapeutics LLC
- Paras Biopharmaceuticals Finland Oy
- Perceive Biotherapeutics Inc
- Phanes Therapeutics Inc
- PharmAbcine Inc
- Phio Pharmaceuticals Corp
- Phision Therapeutics
- PlantForm Corp
- Pleryon Therapeutics Ltd
- Regeneron Pharmaceuticals Inc
- Retrotope Inc
- RheinCell Therapeutics GmbH
- Rophibio Inc
- Rudacure Co Ltd
- SeaBeLife Spas
- Semathera Inc
- Shanghai Novamab Biopharmaceuticals Co Ltd
- SIFI SpA
- SmartinBio
- Splash Pharmaceuticals Inc
- Sustained Nano Systems LLC
- Suzhou Ribo Life Sciences Co Ltd
- Suzhou Stainwei Biotech Inc
- Sylentis SAU
- TALLC Inc
- TechnoPhage SA
- Tianchen Biopharmaceutical (Suzhou) Co Ltd
- TreeFrog Therapeutics SAS
- Trican Biotechnology Co Ltd
- Uni-Bio Science Group Ltd
- Unity Biotechnology Inc
- Valitor Inc
- ViGeneron GmbH
- Visgenx Inc
- Wellstat Ophthalmics Corp
- YD Life Science Co
- Zhejiang Doer Biologics Corp
- Zhuhai Qiwei Biotechnology Co Ltd
- Zydus Lifesciences Ltd
